Birmingham is suing drug manufacturers and health companies, alleging they worked together to establish an “insulin pricing scheme” and inflate the cost of life-saving medicine.

The biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it's really tough to gauge which innovative biotech firms will have something genuinely ground ...